Potential of nanoformulations in malaria treatment
JB Chaves, B Portugal Tavares de Moraes… - Frontiers in …, 2022 - frontiersin.org
Malaria is caused by the protozoan Plasmodium sp and affects millions of people worldwide.
Its clinical form ranges from asymptomatic to potentially fatal and severe. Current treatments …
Its clinical form ranges from asymptomatic to potentially fatal and severe. Current treatments …
Efficacy and safety of therapeutic strategies for human brucellosis: A systematic review and network meta-analysis
SN Silva, G Cota, DM Xavier… - PLOS Neglected …, 2024 - journals.plos.org
Background Human brucellosis is a neglected, re-emerging, and endemic zoonosis in many
countries. The debilitating and disabling potential of the disease is a warning about its …
countries. The debilitating and disabling potential of the disease is a warning about its …
Trends and practices following the 2016 hydroxychloroquine screening guidelines
This study aimed to understand the profile of hydroxychloroquine-treated patients, referral
patterns, and dosing and to assess the adherence of eye care providers to the latest 2016 …
patterns, and dosing and to assess the adherence of eye care providers to the latest 2016 …
Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report
S Lin, C Han, X Lou, ZB Wu - Frontiers in Endocrinology, 2022 - frontiersin.org
Objective A 22-year-old man complaining erectile dysfunction underwent transsphenoidal
surgery for a 2.7 cm sellar mass with total resection and was confirmed at pathology to have …
surgery for a 2.7 cm sellar mass with total resection and was confirmed at pathology to have …
Systemic lupus erythematosus: An approach to pharmacologic interventions
MT El Hussein, C Wong - The Nurse Practitioner, 2023 - journals.lww.com
Drug therapy for patients with systemic lupus erythematosus (SLE) aims to decrease
symptom severity. Pharmacologic interventions are divided into four categories …
symptom severity. Pharmacologic interventions are divided into four categories …
Adverse events in rheumatoid arthritis patients under antimalarial treatment—Is there cardiovascular compromise?
P Santos-Moreno, L Ibatá, S Martínez… - Frontiers in Drug …, 2023 - frontiersin.org
Introduction: The antimalarials chloroquine and hydroxychloroquine have been used for
several decades in treating malaria and some autoimmune diseases—mainly rheumatoid …
several decades in treating malaria and some autoimmune diseases—mainly rheumatoid …
[HTML][HTML] Hydroxychloroquine-Induced Myopathy Responding to Intravenous Immunoglobulin (IVIG)
H Almoallim, A Samkari, A Fallata, H Adam, M Kary… - Cureus, 2023 - ncbi.nlm.nih.gov
Hydroxychloroquine (HCQ), a drug used to treat many diseases such as rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE), has limited reports documenting drug …
(RA) and systemic lupus erythematosus (SLE), has limited reports documenting drug …